Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by One Capital Management LLC

One Capital Management LLC lifted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 26.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 46,121 shares of the company’s stock after purchasing an additional 9,695 shares during the period. One Capital Management LLC’s holdings in Ionis Pharmaceuticals were worth $3,649,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Quarry LP acquired a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $38,000. Johnson Financial Group Inc. acquired a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $44,000. Laurel Wealth Advisors LLC acquired a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $47,000. Bayforest Capital Ltd grew its holdings in shares of Ionis Pharmaceuticals by 608.4% in the fourth quarter. Bayforest Capital Ltd now owns 1,091 shares of the company’s stock valued at $86,000 after purchasing an additional 937 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Ionis Pharmaceuticals by 37.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,137 shares of the company’s stock valued at $90,000 after purchasing an additional 310 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Wall Street Analysts Forecast Growth

IONS has been the subject of a number of research reports. Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Tuesday, April 21st. Barclays lifted their price objective on shares of Ionis Pharmaceuticals from $106.00 to $115.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. HC Wainwright restated a “buy” rating and issued a $125.00 price objective on shares of Ionis Pharmaceuticals in a report on Wednesday, May 27th. Finally, Bank of America boosted their price target on shares of Ionis Pharmaceuticals from $100.00 to $111.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $100.90.

Ionis Pharmaceuticals Trading Down 3.2%

NASDAQ IONS opened at $72.97 on Wednesday. The company has a quick ratio of 4.09, a current ratio of 4.10 and a debt-to-equity ratio of 2.75. Ionis Pharmaceuticals, Inc. has a 52 week low of $33.95 and a 52 week high of $86.74. The stock has a market capitalization of $12.06 billion, a PE ratio of -35.25 and a beta of 0.37. The firm has a 50 day moving average of $74.70 and a two-hundred day moving average of $77.75.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. The company had revenue of $246.09 million during the quarter, compared to analysts’ expectations of $195.57 million. During the same quarter in the previous year, the business posted ($0.93) EPS. The firm’s revenue was up 86.4% on a year-over-year basis. As a group, research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.76 EPS for the current fiscal year.

Insider Activity at Ionis Pharmaceuticals

In other news, EVP Patrick R. O’neil sold 10,148 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $75.25, for a total transaction of $763,637.00. Following the completion of the sale, the executive vice president owned 62,211 shares in the company, valued at approximately $4,681,377.75. The trade was a 14.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brett P. Monia sold 126,670 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $75.20, for a total transaction of $9,525,584.00. Following the sale, the chief executive officer owned 242,662 shares of the company’s stock, valued at $18,248,182.40. This represents a 34.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 456,298 shares of company stock worth $33,713,865 over the last ninety days. 1.81% of the stock is currently owned by insiders.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.